High-yield algorithms, recognition patterns, and exam traps — built for rapid last-minute recall.
Patient age: 60-70 years old (peak incidence)
Chief complaint: Sudden severe unilateral eye pain + headache + nausea/vomiting (often mistaken for migraine or GI pathology)
Vision changes: Blurred vision + halos around lights (pathognomonic for corneal edema)
Trigger history: Recent dark environment exposure (movie theater, dim restaurant) OR recent mydriatic drop use (dilated eye exam) OR anticholinergic medication (antihistamines, TCAs)
The pathognomonic triad:
Additional findings: Cloudy/hazy cornea (from edema), shallow anterior chamber on slit lamp, ciliary flush
| Feature | Angle-Closure | Anterior Uveitis | Migraine |
|---|---|---|---|
| Pupil | Mid-dilated (4-6mm), non-reactive | SMALL (miosis), may be irregular | Normal, reactive |
| Eye hardness | Rock-hard (IOP >40) | Normal/soft | Normal |
| Pain character | Severe eye + headache | Deep ache, photophobia | Throbbing, bilateral |
| Nausea/vomiting | Often present | Absent | May be present |
Key discriminator: Pupil size is the fastest differentiator — mid-dilated = angle-closure; small = uveitis; normal = migraine
Tonometry: IOP >21 mmHg (often 40-80 mmHg) — this confirms elevated pressure
Slit lamp exam: Shallow anterior chamber (best seen with oblique lighting), corneal edema, mid-dilated pupil
Gonioscopy: Closed angle (gold standard, but NOT done acutely — done after IOP controlled)
Goal: Lower IOP emergently to prevent permanent vision loss
Step 1 — Pharmacologic IOP reduction (do ALL of these):
Step 2 — After IOP lowered:
Step 3 — Definitive treatment:
Patient age: Young to middle-aged adult (20-50 years, peak 20-40)
Chief complaint: Deep, aching unilateral eye pain + photophobia (hallmark) + blurred vision
Pain character: Dull, boring pain that worsens with accommodation (reading, near work)
Associated history: HLA-B27-associated conditions — ankylosing spondylitis (young male with back stiffness), reactive arthritis (recent GI/GU infection), inflammatory bowel disease (Crohn's, UC), psoriatic arthritis. May also see in sarcoidosis, Behçet's, or idiopathic
The diagnostic tetrad:
Classic exam findings: Hypopyon (pus layering in anterior chamber, seen in severe cases or HLA-B27), posterior synechiae (iris stuck to lens from inflammation, causes irregular pupil), keratic precipitates (KP) on corneal endothelium
| Feature | Anterior Uveitis | Angle-Closure | Keratitis |
|---|---|---|---|
| Pupil | SMALL (miosis) | Mid-dilated | Normal or small |
| Injection pattern | Ciliary flush (perilimbal) | Diffuse conjunctival | Diffuse or perilimbal |
| IOP | Normal or LOW | Very HIGH (>40) | Normal |
| Cornea | Clear (or KP) | Cloudy/edematous | Ulcer, dendrite, opacity |
| Key differentiator | Cells/flare in AC | Rock-hard eye | Epithelial defect |
Memory aid: "Small pupil, deep pain" = uveitis. "Mid-dilated pupil, rock-hard eye" = angle-closure.
Slit lamp examination: Cells and flare in anterior chamber (diagnostic). Use high magnification with narrow beam.
Look for specific findings:
First episode in young patient: Consider observation without extensive workup (50% idiopathic)
Recurrent or bilateral uveitis: Workup for systemic causes
Goals: Reduce inflammation, prevent posterior synechiae, relieve pain
First-line therapy:
Severe or refractory cases:
Monitoring: Check IOP during steroid treatment (steroids can ↑ IOP in steroid responders)
Chief complaint: Unilateral eye pain + foreign body sensation + photophobia + tearing + blurred vision
Key history clues:
Pain severity: Moderate to severe (worse than simple conjunctivitis, similar to bacterial ulcer)
The diagnosis-locking finding:
Dendritic (branching) ulcer on fluorescein staining — tree-like branching pattern with terminal bulbs ("rose thorns"). This is PATHOGNOMONIC for HSV keratitis.
Additional supportive findings:
| Feature | HSV Keratitis | Bacterial Keratitis | Conjunctivitis |
|---|---|---|---|
| Ulcer pattern | DENDRITIC (branching) | ROUND/OVAL (infiltrative) | No ulcer |
| Discharge | Watery tearing | Purulent (thick, yellow) | Purulent/watery/mucoid |
| Corneal sensation | DECREASED | Normal | Normal |
| Contact lens use | May be present | Often present (Pseudomonas) | Irrelevant |
| Vision loss | Yes (if central) | Yes (if central) | No |
Contact lens wearer + round ulcer: Think Pseudomonas (needs fortified antibiotics: tobramycin + ceftazidime)
Contact lens wearer + dendritic ulcer: Still HSV (contact lens history is a red herring)
Fluorescein staining: Dendritic ulcer pattern is diagnostic (no further testing needed for typical cases)
Corneal sensation testing: Decreased sensation supports HSV (use cotton wisp, compare to unaffected eye)
If atypical or uncertain:
First-line therapy:
Severe or stromal involvement:
If stromal keratitis (immune-mediated):
NEVER give topical steroids in active epithelial HSV keratitis
Chief complaint: Red eye + discharge + irritation
Key negatives that rule out serious pathology:
| Type | Discharge | Laterality | Key Clue | Associations |
|---|---|---|---|---|
| BACTERIAL | Thick, purulent, yellow-green | Unilateral → bilateral | Lids stuck together in AM ("mattering") | S. aureus, S. pneumo, H. flu |
| VIRAL | Watery, clear, serous | Starts unilateral → bilateral | Preauricular lymph node (hallmark) | Adenovirus, URI symptoms |
| ALLERGIC | Watery + stringy mucus | Always bilateral | ITCHING (pathognomonic) | Seasonal, cobblestoning |
Memory aid: "Purulent = Bacterial. Preauricular node = Viral. Itching = Allergic."
1. HYPERACUTE BACTERIAL (Gonococcal)
2. CHLAMYDIAL CONJUNCTIVITIS (Inclusion conjunctivitis)
3. EPIDEMIC KERATOCONJUNCTIVITIS (EKC)
BACTERIAL:
VIRAL:
ALLERGIC:
Presentation: Sudden, PAINLESS, unilateral, PROFOUND vision loss ("like a curtain dropped”)
Vision severity: Count fingers or worse (hand motion, light perception, or no light perception)
Patient demographics: Elderly (>60 yo) with vascular risk factors
Risk factors:
Presentation: Sudden, PAINLESS, unilateral vision loss (LESS severe than CRAO)
Vision severity: Blurred vision, can still read large print (20/100 to 20/400 range, rarely worse)
Patient demographics: Middle-aged to elderly (50-70 yo)
Risk factors:
| Feature | CRAO (Artery) | CRVO (Vein) |
|---|---|---|
| Classic finding | CHERRY-RED SPOT at fovea | BLOOD-AND-THUNDER fundus |
| Retina appearance | Pale, opaque, whitish (ischemic edema) | Diffuse retinal hemorrhages (flame, dot-blot) |
| Vessels | Boxcar segmentation (blood column fragmentation in arteries) | Dilated, tortuous veins |
| Cotton-wool spots | May be present | Present (nerve fiber layer infarcts) |
| APD (afferent pupillary defect) | Present (Marcus Gunn pupil) | Present |
| Vision severity | PROFOUND (CF or worse) | Moderate (can read large print) |
Memory aid: "CRAO = Cherry-red + Complete blindness. CRVO = Hemorrhages everywhere (bloody thunder)."
CRAO — Ocular Emergency (time = retina):
Goal: Restore perfusion within 90-100 minutes (retina tolerates ischemia for ~90 min before irreversible damage)
Workup for CRAO:
CRVO — Urgent (not emergent):
Workup for CRVO:
Classic triad:
Key features:
Risk factors:
Dilated fundoscopy (diagnostic):
If media opacity (vitreous hemorrhage, cataract) blocks view: Use B-scan ultrasound — shows retina separated from choroid
| Feature | Retinal Detachment | Vitreous Hemorrhage | PVD (benign) |
|---|---|---|---|
| Flashes | Present | Absent | Present |
| Floaters | Present (specific location) | Present (diffuse) | Present |
| Visual field defect | TAIN (localized, progressive) | Diffuse blurring (no curtain) | NONE |
| Red reflex | Lost in detached area | Lost globally (blood blocks) | Normal |
| Urgency | URGENT (24-48h surgery) | Urgent (rule out RD) | Routine follow-up |
Key: Curtain = RD. Diffuse blur = vitreous hemorrhage. Flashes + floaters WITHOUT curtain = likely benign PVD (but needs dilated exam to rule out tear).
Confirmed retinal detachment:
Surgical options (done by ophthalmology):
Timing urgency:
Chief complaint: Sudden painless floaters + blurred vision
Floater description (pathognomonic):
Vision quality: Diffuse blurring (NOT localized curtain like retinal detachment)
Pain: PAINLESS (pain suggests globe rupture, endophthalmitis, or angle-closure)
Onset: Sudden (develops over minutes to hours)
Common causes — match vignette context to etiology:
| Cause | Vignette Clue | Mechanism |
|---|---|---|
| Proliferative Diabetic Retinopathy | Long-standing diabetes (>10 years), poor control | Neovascularization ruptures → bleeding |
| Trauma (blunt/penetrating) | History of eye injury, assault, MVA | Direct vessel disruption or retinal tear |
| Retinal Tear/PVD | Elderly, myopic, recent flashes | Vitreous pulls on retina → vessel rupture |
| Sickle Cell Disease | African descent, known sickle cell | Peripheral vaso-occlusion → neovascularization |
| Post-cataract surgery | Recent cataract extraction (days-weeks prior) | Surgical complication (vessel injury, PVD) |
Most common cause overall: Proliferative diabetic retinopathy (~30-40% of cases)
Physical exam:
Diagnostic test:
| Feature | Vitreous Hemorrhage | Retinal Detachment | Hyphema |
|---|---|---|---|
| Blood location | VITREOUS cavity (posterior) | No blood (retina separated) | ANTERIOR chamber (visible) |
| Vision pattern | Diffuse blur (red haze) | Curtain/shadow (localized) | Blur if large, may be normal |
| Flashes | Absent | PRESENT (photopsia) | Absent |
| Trauma history | May be present | May be present | Usually present |
Key: Red haze + diffuse blur = vitreous hemorrhage. Curtain + flashes = retinal detachment. Visible layered blood in anterior chamber = hyphema.
Immediate workup:
Conservative management (if no RD):
Interventions (once fundus visible or if no clearance):
Patient demographics: Young woman (20-40 years old) — peak age 30, female:male = 3:1
The pathognomonic triad:
Additional symptoms:
The diagnostic finding:
Afferent Pupillary Defect (APD / Marcus Gunn pupil)
Fundoscopy findings:
| Feature | Optic Neuritis | Papilledema | Ischemic Optic Neuropathy |
|---|---|---|---|
| Age | 20-40 yo | Any age | >50 yo |
| Pain with eye movement | PRESENT (pathognomonic) | ABSENT | ABSENT |
| APD | PRESENT | ABSENT (bilateral) | PRESENT |
| Laterality | UNILATERAL | BILATERAL | UNILATERAL |
| Vision loss | Early, central scotoma | LATE (enlarged blind spot) | Early, altitudinal defect |
| Disc appearance | Normal or swollen | Bilateral swelling | Pale, swollen |
Memory aid: "Pain with eye movement + APD + young woman = optic neuritis."
MRI brain with gadolinium (CRITICAL):
Visual evoked potentials (VEP):
Other tests (if atypical presentation):
Acute treatment (Optic Neuritis Treatment Trial — ONTT):
Long-term MS prevention:
Prognosis: 90% recover to ≥20/40 vision within 1 year (most recovery in first 3 months)
Presentation: Usually ASYMPTOMATIC until late (detected on screening exam)
When symptomatic (late disease):
Patient demographics & risk factors:
The diagnostic triad:
CRITICAL CONCEPT: IOP may be NORMAL
Classic visual field patterns:
Essential tests for diagnosis:
First-line medication:
Second-line agents (if monotherapy insufficient):
Surgical options (if medications fail):
| Open-Angle Glaucoma | Acute Angle-Closure |
|---|---|
| CHRONIC, painless, asymptomatic | ACUTE, painful, severe headache |
| Peripheral vision loss (tunnel vision) | Blurred vision + halos around lights |
| IOP may be NORMAL (<21 mmHg) | IOP very HIGH (>40 mmHg) |
| Gonioscopy: Open angle | Gonioscopy: Closed angle |
| Treatment: Medications (prostaglandin analogs) | Treatment: Emergency IOP reduction → LPI |
Key: Open-angle = chronic, painless, asymptomatic. Angle-closure = acute, painful, emergency.
Patient demographics: Type 1 or Type 2 diabetes, duration >5-10 years
Presentation scenarios:
Risk factors for progression:
| Stage | Fundoscopic Findings | Vision | Management |
|---|---|---|---|
| Mild NPDR | Microaneurysms only | Normal | Annual dilated exam + optimize glucose control |
| Moderate NPDR | Dot-blot hemorrhages, hard exudates, cotton-wool spots | Normal or mild blur | Dilated exam every 6-12 months |
| Severe NPDR | 4-2-1 Rule: Hemorrhages in 4 quadrants, Venous beading in 2+ quadrants, IRMA in 1+ quadrant | Decreasing | Close follow-up (2-4 months), consider PRP |
| Proliferative (PDR) | NEOVASCULARIZATION (new vessels on disc NVD or elsewhere NVE) | Risk of VH/RD | IMMEDIATE referral for pan-retinal photocoagulation (PRP) |
| Macular Edema | Hard exudates in macula, retinal thickening (OCT shows fluid) | Central blur | Anti-VEGF injections (ranibizumab, bevacizumab, aflibercept) |
Key: NPDR = Non-Proliferative (no new vessels). PDR = Proliferative (neovascularization present). Macular edema can occur at ANY stage.
Microaneurysms:
Dot-blot hemorrhages:
Hard exudates:
Cotton-wool spots:
Venous beading:
IRMA (Intraretinal Microvascular Abnormalities):
Neovascularization (PDR hallmark):
Medical management (ALL stages):
Proliferative Diabetic Retinopathy (PDR):
Diabetic Macular Edema (DME):
Vitrectomy: If non-clearing vitreous hemorrhage OR tractional retinal detachment
Chief complaint: Sudden diplopia (double vision) + ptosis (drooping eyelid)
Eye position: Eye deviated "DOWN and OUT"
Additional findings:
The CRITICAL bifurcation — pupil involvement determines urgency:
| PUPIL-SPARING (Normal Pupil) | PUPIL-INVOLVED (Dilated Pupil) |
|---|---|
| Pupil size: | Pupil size: |
| Normal or small, REACTIVE to light | DILATED (4-6 mm), NON-REACTIVE |
| Mechanism: | Mechanism: |
| Ischemic (microvascular) — affects nerve CORE (motor fibers), spares periphery (pupil fibers) | Compressive — affects entire nerve including peripheral pupillary fibers |
| Etiology: | Etiology: |
| MEDICAL: Diabetes, hypertension (microvascular ischemia) | SURGICAL EMERGENCY: Posterior communicating artery (PComm) aneurysm |
| Patient age: | Patient age: |
| >50 yo, vascular risk factors | Any age (but aneurysm more common in younger patients) |
| Workup: | Workup: |
| Check HbA1c, BP, lipids. Observe (usually resolves in 3 months). | EMERGENT CTA or MRA (rule out aneurysm) → neurosurgery consult SAME DAY |
| Prognosis: | Prognosis: |
| Resolves in 3 months (spontaneous recovery) | If aneurysm ruptures → subarachnoid hemorrhage (high mortality) |
Memory aid: "Pupil-sparing = Medical (diabetes). Pupil-involved = Surgical (aneurysm until proven otherwise)."
| Feature | CN III Palsy | CN VI Palsy | Horner Syndrome |
|---|---|---|---|
| Eye position | DOWN and OUT | Esotropia (medial, can't ABduct) | Normal alignment |
| Ptosis | PRESENT (complete) | ABSENT | PRESENT (mild, partial) |
| Pupil | Normal OR dilated | Normal | MIOSIS (small, constricted) |
| Key clue | Ptosis + down/out eye | Esotropia, NO ptosis | Ptosis + SMALL pupil + anhidrosis |
Key: CN III = down-and-out + ptosis. CN VI = esotropia (medial deviation), no ptosis. Horner = ptosis + miosis (small pupil).
Chief complaint: Headache + transient vision loss ("greyouts" or "blackouts" lasting seconds)
Headache characteristics (raised ICP pattern):
Transient visual obscurations (TVOs):
Additional symptoms:
Patient demographics — two main scenarios:
| Idiopathic Intracranial Hypertension (IIH) | Secondary Causes |
|---|---|
| Young obese woman of childbearing age ("classic presentation") | Any age — look for focal neurologic signs |
| Recent weight gain, OCPs, tetracycline, vitamin A | Brain tumor, venous sinus thrombosis, meningitis, SAH |
Key: IIH = young obese woman, no focal signs. Secondary = any age, may have focal deficits.
Fundoscopy (diagnostic):
Critical negatives:
| Feature | Papilledema | Optic Neuritis | Optic Disc Drusen |
|---|---|---|---|
| Laterality | BILATERAL | UNILATERAL | Bilateral |
| APD | ABSENT | PRESENT | ABSENT |
| Pain | Headache (NO eye pain) | Pain with eye movement | None |
| Vision loss | LATE (TVOs, enlarged blind spot) | EARLY (subacute, central scotoma) | Usually none (incidental finding) |
| Venous engorgement | PRESENT | Absent | Absent |
Key: Papilledema = bilateral + NO APD + NO early vision loss. Optic neuritis = unilateral + APD + pain with eye movement.
Step 1 — Neuroimaging (MANDATORY before LP):
Step 2 — Lumbar puncture (if imaging negative):
Idiopathic Intracranial Hypertension (IIH):
Secondary causes: Treat underlying (tumor resection, anticoagulation for venous thrombosis, etc.)
Correct: C) Acute angle-closure glaucoma
Concept: Acute angle-closure glaucoma - classic vignette pattern Interpretation
Why C: Sudden severe unilateral eye pain with headache and nausea/vomiting, halos around lights (corneal edema), a mid-dilated non-reactive pupil, and a rock-hard eye in an older patient after dark-environment exposure is the classic acute angle-closure attack. The dark environment causes mydriasis that precipitates the block; IOP is typically 40-80 mmHg.
Discriminator: The triad of mid-dilated non-reactive pupil, rock-hard eye, and halos around lights (corneal edema) is pathognomonic; the movie theater trigger is the classic precipitant.
| A) Migraine with aura | Migraine has a normal reactive pupil and no halos; nausea may overlap but the pupil findings exclude it |
| B) Anterior uveitis | Anterior uveitis gives a SMALL (miotic) pupil and a normal/soft eye - the opposite pupil finding |
| D) Acute bacterial conjunctivitis | Bacterial conjunctivitis has discharge, a normal pupil, and no severe pain, halos, or vomiting |
| E) Optic neuritis | Optic neuritis is subacute with pain on eye movement and a central scotoma - not a rock-hard acute eye |
Trap: Pattern trap - the headache, nausea, and vomiting are written to seduce you into migraine or GI pathology; the mid-dilated non-reactive pupil is the lock.
Future alert: Rock-hard eye + mid-dilated fixed pupil + halos = angle-closure; treat as an emergency, never dilate.
Correct: B) Pupil size and reactivity
Concept: Pupil size is the fastest differentiator between angle-closure and uveitis Analysis
Why B: Pupil size is the fastest differentiator: mid-dilated (4-6 mm) non-reactive pupil = angle-closure; small constricted pupil (miosis from ciliary spasm) = anterior uveitis; normal reactive pupil = migraine. The two painful red-eye emergencies are separated on the pupil before anything else.
Discriminator: Mid-dilated = angle-closure; small = uveitis; normal = migraine - pupil is the one-stop discriminator.
| A) The degree of conjunctival injection | Both can show injection - angle-closure is diffuse conjunctival, uveitis is a perilimbal ciliary flush; neither is the fastest differentiator |
| C) The presence of nausea and vomiting | Nausea/vomiting is present in angle-closure but is not the discriminating feature; overlap is common |
| D) Visual acuity at presentation | Both cause blurred vision - acuity overlaps and does not separate the two |
| E) The patient's age at presentation | Age overlaps (60-70 peak for angle-closure vs 20-40 for uveitis) - demographics suggest but do not lock the diagnosis |
Trap: Overlap trap - both are painful red eyes with blurring; the pupil never lies and resolves it in seconds.
Future alert: Painful red eye -> check the pupil first: mid-dilated fixed = angle-closure, small = uveitis.
Correct: B) Lower IOP with timolol, apraclonidine, acetazolamide, and mannitol, then give pilocarpine once IOP is controlled
Concept: Treatment sequencing - lower IOP first, pilocarpine after control Analysis
Why B: The goal is emergent IOP reduction: topical beta-blocker (timolol) plus alpha-agonist (apraclonidine) to decrease aqueous production, systemic acetazolamide, and a hyperosmotic agent (mannitol). Pilocarpine constricts the pupil to open the angle but must be given AFTER IOP is lowered - if given when IOP is above 40, it paradoxically worsens ischemia and angle closure.
Discriminator: IOP reduction first; pilocarpine second. At very high IOP the miotic can paradoxically worsen the block.
| A) Give pilocarpine immediately to constrict the pupil and open the angle | Pilocarpine is correct but the timing is wrong - at IOP >40 it paradoxically worsens closure |
| C) Start topical steroids and cycloplegics before measuring IOP again | Steroids and cycloplegics are uveitis therapy, not angle-closure; here they delay the emergency IOP reduction |
| D) Instill mydriatic drops to break the attack | Mydriatics are NEVER given in angle-closure - they worsen the block |
| E) Give pilocarpine only in the unaffected eye as prophylaxis | The affected eye needs the same stepwise treatment; the fellow eye needs prophylactic laser iridotomy, not pilocarpine alone |
Trap: Sequence trap - pilocarpine is the right drug but the wrong first step; high IOP flips it from helpful to harmful.
Future alert: Angle-closure: lower IOP first (beta-blocker + alpha-agonist + acetazolamide + mannitol), then pilocarpine, then bilateral LPI.
Correct: C) Perform prophylactic laser peripheral iridotomy on the left eye
Concept: Fellow eye prophylaxis - 50% risk of an attack Interpretation
Why C: The fellow eye has a 50% risk of developing an attack within 5 years without prophylactic treatment, so laser peripheral iridotomy (LPI) should be performed on BOTH eyes. LPI creates a hole in the iris to equalize pressure between chambers and is the definitive treatment.
Discriminator: Fellow eye risk is 50% - the contralateral eye gets prophylactic LPI, not observation.
| A) Reassure the patient and review in one year | A 50% risk is far too high to observe; the fellow eye needs prophylactic LPI |
| B) Prescribe pilocarpine drops to the left eye for life | Pilocarpine is not a definitive prophylaxis for the fellow eye - LPI is |
| D) Schedule gonioscopy only if halos develop | Waiting for symptoms forfeits the prophylactic window; the procedure is preventive |
| E) Start chronic oral acetazolamide | Chronic oral acetazolamide is not indicated for an asymptomatic open-angle fellow eye |
Trap: Laterality trap - treating only the affected eye is a classic error; the contralateral eye is at 50% risk.
Future alert: After any angle-closure attack, prophylactic LPI on both eyes - fellow eye risk is 50% within 5 years.
Correct: B) Acute anterior uveitis
Concept: Anterior uveitis - diagnostic tetrad Interpretation
Why B: The diagnostic tetrad of anterior uveitis: ciliary flush (perilimbal injection), cells and flare in the anterior chamber, a small (constricted) pupil from ciliary spasm, and pain on accommodation. The deep, boring pain with photophobia in a young adult is the classic pattern.
Discriminator: Ciliary flush + cells/flare + miosis + pain on accommodation = the uveitis tetrad.
| A) Acute angle-closure glaucoma | Angle-closure gives a mid-dilated non-reactive pupil and rock-hard eye - the opposite pupil and pressure profile |
| C) Viral conjunctivitis | Conjunctivitis has discharge, no photophobia, no cells/flare, and no pain with accommodation |
| D) Herpetic keratitis | Herpetic keratitis shows a dendritic corneal ulcer on fluorescein, not anterior chamber cells |
| E) Scleritis | Scleritis is deep scleral inflammation with a bluish hue, not cells/flare in the anterior chamber |
Trap: Compare-and-contrast trap - every painful red eye is on the differential; the small pupil plus cells/flare locks uveitis.
Future alert: Cells + flare + small pupil + ciliary flush = anterior uveitis; treat with topical steroids and a cycloplegic.
Correct: B) Topical corticosteroids plus a cycloplegic agent
Concept: First-line uveitis therapy - steroids + cycloplegic Recall
Why B: First-line therapy for anterior uveitis is topical corticosteroids (prednisolone acetate 1% initially every 1-2 hours) to reduce inflammation, plus a cycloplegic agent (cyclopentolate or homatropine) that dilates the pupil, relieves ciliary spasm for pain relief, and prevents posterior synechiae formation.
Discriminator: Steroids fight the inflammation; the cycloplegic prevents synechiae and relieves the accommodative pain.
| A) Topical antibiotics plus oral antivirals | Uveitis is inflammatory, not infectious - antibiotics are wrong unless an ulcer/infiltrate suggests endophthalmitis |
| C) Oral acetazolamide plus pilocarpine | Acetazolamide and pilocarpine are angle-closure drugs - the wrong mechanism for uveitis |
| D) Topical beta-blockers plus hyperosmotics | IOP-lowering agents do nothing for intraocular inflammation and do not prevent synechiae |
| E) No treatment - watchful waiting | Uveitis untreated causes synechiae, cataract, and glaucoma - it requires active therapy |
Trap: Drug-class trap - the examiner plants angle-closure therapy to test whether you know uveitis is an inflammatory disease.
Future alert: First-line uveitis: topical prednisolone acetate 1% + cycloplegic; the cycloplegic prevents synechiae and relieves pain.
Correct: C) RPR/VDRL for syphilis
Concept: Syphilis - the great masquerader - always checked in uveitis Recall
Why C: RPR/VDRL is mandatory in every uveitis workup because syphilis is 'the great masquerader' and can present as uveitis. ANA, ACE, CXR, and Quantiferon are ordered when autoimmune or granulomatous disease is suspected; they are not universal mandates.
Discriminator: Syphilis must be excluded in every uveitis patient - RPR/VDRL is the non-negotiable screening test.
| A) Antinuclear antibody (ANA) | ANA is for suspected lupus - not a universal uveitis screen |
| B) Serum angiotensin-converting enzyme (ACE) | ACE is for sarcoidosis - only when granulomatous or systemic features suggest it |
| D) Quantiferon tuberculin testing | Quantiferon/PPD checks TB, especially in granulomatous uveitis - not the universal mandate |
| E) Rheumatoid factor | Rheumatoid factor is not part of the standard uveitis panel - joint symptoms would guide it |
Trap: Mandate trap - many pick the autoimmune test; RPR/VDRL is the one test that is ALWAYS required.
Future alert: Uveitis workup: HLA-B27, RPR/VDRL (mandatory - syphilis, the great masquerader), ANA/ACE/CXR, Quantiferon if granulomatous.
Correct: B) HLA-B27-associated spondyloarthropathy (reactive arthritis)
Concept: HLA-B27-associated conditions - ankylosing spondylitis and reactive arthritis Interpretation
Why B: Young men with anterior uveitis and inflammatory back pain (ankylosing spondylitis) or a recent GI/GU infection (reactive arthritis) are the classic HLA-B27-associated presentations. HLA-B27 is found in about 50% of acute anterior uveitis cases versus 8% of the general population.
Discriminator: Back stiffness + recent diarrhea + acute uveitis in a young man = spondyloarthropathy; always ask about back pain, diarrhea, and bowel symptoms.
| A) Sarcoidosis | Sarcoidosis causes granulomatous uveitis and has pulmonary findings - not this history |
| C) Systemic lupus erythematosus | Lupus is autoimmune (ANA-driven) and does not classically present with back stiffness and reactive diarrhea |
| D) Herpes zoster | Herpes zoster would show a vesicular dermatomal rash, not this seronegative pattern |
| E) Tuberculosis | TB causes granulomatous uveitis - the diarrhea and back stiffness point to a spondyloarthropathy instead |
Trap: Association trap - the back stiffness plus diarrhea is the HLA-B27 signature; never dismiss them as incidental history.
Future alert: Anterior uveitis + back pain, diarrhea, or bowel symptoms = ask about HLA-B27-associated disease.
Correct: B) Herpes simplex keratitis
Concept: Dendritic ulcer - pathognomonic for HSV keratitis Interpretation
Why B: A dendritic (branching) ulcer with terminal bulbs on fluorescein staining is pathognomonic for HSV keratitis - the rose-thorns pattern. Contact lens use is a red herring here: a contact lens wearer with a dendritic ulcer still has HSV, not bacterial keratitis.
Discriminator: Dendritic ulcer + terminal bulbs = HSV regardless of contact lens history; lens use only redirects you when the ulcer is round.
| A) Bacterial keratitis (Pseudomonas) | Bacterial keratitis gives a round/oval infiltrative ulcer with purulent discharge - not branching dendrites |
| C) Viral conjunctivitis | Conjunctivitis has no corneal ulcer, no vision loss, and no photophobia |
| D) Herpes zoster ophthalmicus | Zoster ophthalmicus has a vesicular dermatomal rash and may show coarser pseudodendrites |
| E) Fungal keratitis | Fungal keratitis typically follows vegetable-matter trauma with feathery infiltrates - not dendrites |
Trap: Red-herring trap - the contact lens history is planted to push you toward Pseudomonas; the dendrite is the lock.
Future alert: Branching ulcer with terminal bulbs on fluorescein = HSV keratitis; the lens history is irrelevant once you see the dendrite.
Correct: B) Topical ganciclovir 0.15% gel 5 times daily or trifluridine 1% drops
Concept: HSV keratitis first-line - topical antivirals Recall
Why B: First-line therapy is a topical antiviral: ganciclovir 0.15% gel 5 times daily OR trifluridine 1% drops 9 times daily (more frequent dosing). Severe or stromal involvement warrants oral acyclovir 400 mg 5 times daily or valacyclovir 500 mg three times daily.
Discriminator: Topical antivirals are the non-negotiable first line; steroids in active epithelial HSV are the cardinal error.
| A) Topical steroids to suppress the immune response | Topical steroids in active epithelial HSV are NEVER given - they allow progression to a geographic ulcer and permanent scarring |
| C) Oral antibiotics plus topical erythromycin | Antibiotics treat bacteria, not HSV; they do nothing for the dendritic ulcer |
| D) Laser photocoagulation of the ulcer | Laser has no role in treating an epithelial HSV ulcer |
| E) Artificial tears only and reassurance | Artificial tears provide no antiviral effect; active HSV requires specific therapy |
Trap: Safety trap - the most dangerous mistake in herpetic keratitis is the steroid, and the exam will offer it as bait.
Future alert: HSV keratitis: ganciclovir gel or trifluridine drops; oral acyclovir/valacyclovir for severe or stromal disease.
Correct: B) Suspect Pseudomonas and start fortified tobramycin plus ceftazidime
Concept: Round ulcer in a lens wearer = bacterial keratitis (Pseudomonas) Interpretation
Why B: A contact lens wearer with a round/oval infiltrative ulcer and purulent discharge has bacterial keratitis - Pseudomonas until proven otherwise - and needs fortified antibiotics (tobramycin + ceftazidime). The round morphology is the opposite of the dendritic HSV pattern.
Discriminator: Round ulcer = bacterial; dendritic ulcer = HSV. The lens history matters only when the ulcer is round.
| A) Start topical antivirals because the ulcer is dendritic | The ulcer is explicitly round, not dendritic - the branching pattern is absent |
| C) Reassure the patient that contact lens ulcers resolve spontaneously | Bacterial keratitis in a lens wearer can perforate; it demands urgent fortified antibiotics |
| D) Add topical steroids to speed healing | Steroids are contraindicated in active bacterial keratitis - they would accelerate melting |
| E) Refer for laser peripheral iridotomy | LPI treats angle-closure - irrelevant to a corneal ulcer |
Trap: Morphology trap - dendrite = HSV, round = bacteria; the lens history is decisive only in the round pattern.
Future alert: Lens wearer + round infiltrative ulcer = Pseudomonas; fortified tobramycin + ceftazidime, urgent.
Correct: A) The nasal tip rash (Hutchinson sign) signals high risk of ocular involvement and needs urgent ophthalmology care
Concept: Herpes zoster ophthalmicus - Hutchinson sign predicts ocular involvement Analysis
Why A: A vesicular dermatomal rash in the V1 distribution with a coarse corneal lesion is herpes zoster ophthalmicus (HZO). The Hutchinson sign - rash on the tip of the nose (innervated by the nasociliary nerve) - signals high risk of ocular involvement, and these patients need urgent ophthalmology evaluation.
Discriminator: Tip-of-nose rash = nasociliary nerve involvement = high risk of eye disease; HZO pseudodendrites are coarser and less branching than HSV.
| B) The lesion is a typical HSV dendrite and needs no further workup | Zoster pseudodendrites are coarser and less branching than HSV dendrites and are managed differently - this is not typical HSV |
| C) The rash is unrelated to the eye findings | The dermatomal V1 rash is exactly what links the skin and eye in HZO |
| D) This is bacterial conjunctivitis requiring topical antibiotics | No discharge and a vesicular rash with corneal involvement is not bacterial conjunctivitis |
| E) The corneal lesion is viral conjunctivitis with a pseudomembrane | Conjunctivitis has no corneal ulcer and no dermatomal rash - this is HZO |
Trap: Eponym trap - Hutchinson sign is the classic high-yield marker; missing it misses the eye risk.
Future alert: V1 vesicular rash + corneal lesion = HZO; rash on nasal tip (Hutchinson sign) = urgent ophthalmology.
Correct: B) Bacterial conjunctivitis
Concept: Discharge type = diagnosis - purulent = bacterial Interpretation
Why B: Thick purulent discharge with lids stuck together in the morning (mattering) is the bacterial signature, typically from S. aureus, S. pneumoniae, or H. influenzae. The discharge pattern is the recognition trigger: purulent = bacterial, watery with preauricular node = viral, itching = allergic.
Discriminator: Purulent + mattering = bacterial; normal vision and no photophobia keep this in the benign conjunctivitis lane.
| A) Viral conjunctivitis | Viral conjunctivitis gives watery serous discharge with a preauricular lymph node - not purulent mattering |
| C) Allergic conjunctivitis | Allergic conjunctivitis is always bilateral, watery with stringy mucus, and dominates with itching |
| D) Anterior uveitis | Uveitis has photophobia, deep pain, and cells/flare - all absent here |
| E) Herpetic keratitis | Herpetic keratitis has corneal ulceration, photophobia, and vision loss |
Trap: Discharge trap - the character of the discharge is the diagnosis; do not over-read the red eye.
Future alert: Purulent discharge + eyelids stuck in the morning = bacterial conjunctivitis; topical erythromycin or a fluoroquinolone.
Correct: C) Viral conjunctivitis (adenovirus)
Concept: Preauricular lymph node = viral (adenovirus) hallmark Interpretation
Why C: Watery serous discharge plus a preauricular lymph node in the setting of a URI is viral conjunctivitis - the adenovirus hallmark. The preauricular node is the recognition trigger: it marks adenoviral disease, not bacterial.
Discriminator: Preauricular lymphadenopathy = viral conjunctivitis; do not miss the node, because it redirects the whole diagnosis.
| A) Bacterial conjunctivitis | Bacterial conjunctivitis gives purulent mattering - not a watery discharge with an adenopathy |
| B) Gonococcal conjunctivitis | Gonococcal disease is hyperacute with copious pus and chemosis, not watery with mild adenopathy |
| D) Allergic conjunctivitis | Allergic conjunctivitis is itching-dominated, bilateral, and stringy - no URI or tender node |
| E) Herpetic keratitis | Herpetic keratitis has corneal ulceration and pain - not a self-limited watery red eye |
Trap: Hallmark trap - the preauricular node is the single most important clue; missing it sends you to the wrong antibiotic.
Future alert: Watery discharge + preauricular node + URI = adenovirus; supportive care only, strict hand hygiene.
Correct: B) Systemic ceftriaxone 1 g IM/IV plus saline irrigation
Concept: Hyperacute gonococcal conjunctivitis - systemic therapy required Analysis
Why B: Copious purulent discharge, severe chemosis, and onset under 12 hours is hyperacute gonococcal conjunctivitis, which can perforate the cornea within 24-48 hours if untreated. Treatment demands systemic ceftriaxone 1 g IM/IV plus saline irrigation - topical therapy alone is insufficient.
Discriminator: Rapid copious pus + chemosis = gonococcus; systemic ceftriaxone is mandatory because topical alone cannot prevent perforation.
| A) Topical moxifloxacin drops alone | Topical drops alone are insufficient for gonococcal conjunctivitis - the infection can perforate the cornea |
| C) Oral antihistamines and cool compresses | Antihistamines treat allergy - this is a hyperacute purulent infection, not itching |
| D) Topical steroids for two days | Steroids are contraindicated in an active purulent infection and would accelerate perforation |
| E) Oral acyclovir | Acyclovir treats HSV - this is a bacterial emergency |
Trap: Route trap - the examiner offers the easy topical answer; gonococcus requires systemic antibiotics or the cornea perforates.
Future alert: Hyperacute purulent conjunctivitis = gonococcus: ceftriaxone 1 g IM/IV + irrigation, urgent - cornea can perforate in 24-48 h.
Correct: B) Chlamydia - treat with oral azithromycin or doxycycline
Concept: Neonatal chlamydial conjunctivitis - timing 5-14 days = chlamydia Analysis
Why B: Chlamydial conjunctivitis in neonates (ophthalmia neonatorum) appears 5-14 days after birth, while gonorrhea appears earlier at 2-5 days. Chronic mucopurulent discharge with follicles points to chlamydia; treatment is systemic - oral azithromycin 1 g single dose or doxycycline 100 mg twice daily for 7 days - and the partner must be treated.
Discriminator: Neonatal timing is the discriminator: 5-14 days = chlamydia (systemic azithromycin/doxycycline), 2-5 days = gonorrhea.
| A) Gonorrhea - treat with ceftriaxone IV | Gonorrhea presents at 2-5 days with copious hyperacute purulence - this neonate's day-10 follicular picture is chlamydia |
| C) Adenovirus - supportive care only | Adenovirus does not cause a neonatal ophthalmia with these features |
| D) Staph aureus - topical erythromycin only | S. aureus conjunctivitis is possible, but the neonatal timing and follicles point to chlamydia, and topical treatment alone is insufficient |
| E) Herpes simplex - systemic acyclovir | HSV neonatorum has vesicular skin lesions and often systemic illness - not this isolated follicular discharge |
Trap: Timing trap - days after birth split chlamydia (5-14) from gonorrhea (2-5); the systemic requirement is the treatment trap.
Future alert: Neonatal conjunctivitis: 5-14 days + follicles = chlamydia -> systemic azithromycin/doxycycline, treat partner; 2-5 days hyperacute = gonorrhea.
Correct: B) Central retinal artery occlusion
Concept: CRAO - cherry-red spot and boxcar segmentation Interpretation
Why B: Painless sudden severe vision loss with retinal whitening and a cherry-red spot is the signature of central retinal artery occlusion: the ischemic edematous retina appears white, while the macula (thin, perfused by choroid) stays red - the cherry-red spot. Boxcar segmentation is blood column fragmentation in the vessels.
Discriminator: Cherry-red spot = the whole CRAO diagnosis; the retina blanches white except for the fovea's choroidal red dot.
| A) Central retinal vein occlusion | CRVO gives blood-and-thunder fundus with dilated tortuous veins and dot-blot hemorrhages, not a cherry-red spot |
| C) Acute angle-closure glaucoma | Angle-closure is a painful red eye with a rock-hard globe and mid-dilated pupil - not painless visual loss |
| D) Vitreous hemorrhage | Vitreous hemorrhage gives a red haze or absent red reflex, not a cherry-red spot |
| E) Optic neuritis | Optic neuritis is subacute with pain on eye movement and a central scotoma in a younger patient |
Trap: Spot-name trap - 'cherry-red spot' is the single most tested eponym in retinal vascular disease; anchor it to CRAO.
Future alert: Painless sudden vision loss + cherry-red spot + boxcar segmentation = CRAO - an ophthalmic emergency.
Correct: B) Order temporal artery biopsy BEFORE giving steroids
Concept: Giant cell arteritis - biopsy before steroids Analysis
Why B: In a patient over 50 with CRAO and elevated inflammatory markers, giant cell arteritis (GCA) is the feared cause: untreated, it can blind the other eye within days. The biopsy should be obtained within 7 days - and steroids started immediately after, because steroids do not silence the biopsy as long as treatment begins after sampling.
Discriminator: The CRAO-plus-high-ESR pairing is GCA until proven otherwise - biopsy first, then high-dose steroids.
| A) Start intravenous methylprednisolone and THEN order the ESR/CRP | Steroids before biopsy can make the biopsy falsely negative when the diagnosis matters most |
| C) Give oral aspirin and review in one week | Aspirin alone in GCA risks contralateral blindness - this is an emergency requiring steroids |
| D) Start topical anti-glaucoma drops | Glaucoma drops have no role in arterial occlusion |
| E) Refer for laser photocoagulation of the macula | Laser has no role in an established CRAO; the systemic inflammatory disease is the emergency |
Trap: Order trap - steroids must not precede the biopsy; the classic mistake is treating first and losing the diagnostic window.
Future alert: CRAO in a patient over 50 + high ESR/CRP = giant cell arteritis; temporal artery biopsy within 7 days, steroids starting after biopsy.
Correct: A) Hypertension
Concept: CRVO - blood-and-thunder fundus, hypertension is the driver Interpretation
Why A: The blood-and-thunder fundus - diffuse retinal hemorrhages with dilated tortuous veins in all quadrants - is central retinal vein occlusion. Hypertension is the most common associated risk factor, and the presentation is a painless moderate visual loss developing over hours to a day.
Discriminator: Blood-and-thunder fundus = CRVO; the driver is HTN, not the vasculitis that characterizes CRAO in the elderly.
| B) Giant cell arteritis | GCA causes CRAO presentations with high ESR, not a blood-and-thunder vein-occlusion fundus |
| C) Optic neuritis | Optic neuritis is unilateral pain with eye movement, a central scotoma, and a normal or swollen disc - no venous engorgement |
| D) Contact lens use | Contact lens use causes keratitis, not a retinal vascular occlusion |
| E) Herpes simplex infection | HSV is corneal disease - irrelevant to a retinal venous event |
Trap: Compare trap - CRAO (cherry-red) vs CRVO (blood-and-thunder); the veins and hemorrhages lock the venous side.
Future alert: Blood-and-thunder fundus = CRVO; check BP as the chief risk factor; look for a cause in younger patients.
Correct: B) Anti-VEGF injection (e.g., ranibizumab or aflibercept) for macular edema
Concept: CRVO - anti-VEGF for macular edema, no acute mechanical therapy Analysis
Why B: There is no acute medical treatment that restores venous flow in CRVO; the two tasks are managing the complications - macular edema and neovascularization. Anti-VEGF injections (ranibizumab, aflibercept, bevacizumab) are first-line for CRVO-related macular edema and improving acuity.
Discriminator: CRVO has no acute reperfusion therapy; treat the complications - anti-VEGF for edema, PRP for neovascularization.
| A) Immediate intravenous thrombolysis | Thrombolysis has no proven role in CRVO and risks hemorrhage - the occlusion is not an acute arterial emergency |
| C) Temporal artery biopsy | Biopsy is for suspected GCA in CRAO - not venous occlusion without inflammatory markers |
| D) Systemic anticoagulation with warfarin | Anticoagulation does not treat CRVO and risks worsening the hemorrhage burden |
| E) Immediate laser peripheral iridotomy | LPI treats angle-closure - irrelevant to a retinal vein occlusion |
Trap: Intervention trap - the exam wants you to reach for an acute treatment; the correct move is complication management.
Future alert: CRVO management = surveillance for neovascular glaucoma (90-day glaucoma) + anti-VEGF for macular edema + PRP if neovascularization.
Correct: B) Neovascular glaucoma from retinal ischemia - treat with panretinal photocoagulation (PRP) plus IOP control
Concept: Neovascular glaucoma - the 90-day glaucoma of CRVO Analysis
Why B: Neovascular glaucoma develops 6 weeks to 3 months after a severe CRVO when retinal ischemia releases VEGF, driving iris and angle neovascularization that blocks outflow ('90-day glaucoma'). The definitive treatment when the retina can still be treated is panretinal photocoagulation (PRP) plus IOP control - the underlying ischemia must be eliminated.
Discriminator: Iris new vessels after CRVO = neovascular glaucoma; PRP treats the cause (ischemia), drops only treat the number.
| A) Primary open-angle glaucoma - start prostaglandin analogues | The angle is blocked by new vessels, not by an open-angle mechanism - prostaglandins do nothing for the neovascularization |
| C) Acute angle-closure from a swollen lens - laser iridotomy | The lens has not swollen; the mechanism is iris/angle neovascularization, not iridocorneal angle closure |
| D) Uveitic glaucoma - start steroids | Steroids treat inflammation - this is ischemia-driven new vessel growth, not uveitis |
| E) Steroid-induced glaucoma - stop all IOP drops | Steroid-induced glaucoma is a different story - this patient never had steroids and the iris vessels are the clue |
Trap: Mechanism trap - recognize the ischemic origin ('90-day glaucoma') and treat the retina with PRP, not just the pressure.
Future alert: CRVO + red painful eye + iris new vessels = neovascular glaucoma; PRP + IOP control; this is why CRVO is followed at 6 weeks.
Correct: C) Rhegmatogenous retinal detachment
Concept: Retinal detachment - the classic prodrome triad Interpretation
Why C: Flashes (photopsia from vitreous traction), a sudden increase in floaters, and a dark curtain/shadow that spreads are the classic prodrome of rhegmatogenous retinal detachment. High myopia predisposes through lattice degeneration and vitreous changes; the curtain progressing from below completes the pattern.
Discriminator: Flashes + new floaters + a curtain = detachment until proven otherwise; myopia is the predisposing soil.
| A) Central retinal vein occlusion | CRVO is painless diffuse blur with a blood-and-thunder fundus - no flashes, floaters, or curtain |
| B) Cystoid macular edema | Cystoid macular edema gives central blurred vision with no flashes or curtain |
| D) Optic neuritis | Optic neuritis is pain on eye movement with central scotoma in a young adult - no floaters or curtain |
| E) Acute anterior uveitis | Uveitis is a painful red eye with photophobia - not a painless shadow with floaters |
Trap: Triad trap - flashes, floaters, curtain is the detachment sequence; a curtain is never 'just floaters'.
Future alert: Flashes + new floaters + curtain, especially in a myope = rhegmatogenous RD - emergency, macula-on status decides urgency.
Correct: B) B-scan ultrasound
Concept: B-scan ultrasound when the retina cannot be seen Interpretation
Why B: When media opacity (hemorrhage or cataract) prevents fundus visualization in a patient with a suspected detachment, B-scan ultrasound is the investigation of choice - it shows the detached retina and rules it in or out. The clue in the stem is the hazy vitreous blocking direct examination.
Discriminator: Cannot see the fundus + suspected RD = B-scan ultrasound; it penetrates the opaque media.
| A) Fluorescein angiography | Angiography images the retinal circulation, but cannot visualize anatomy through haze |
| C) OCT of the macula | OCT images the macula in cross-section but cannot see the peripheral retina through vitreous haze |
| D) Visual field testing | Perimetry is a functional test that cannot confirm a structural detachment |
| E) Electroretinography | ERG tests retinal function, not structural detachment |
Trap: Tool trap - the hazy fundus is the planted clue; B-scan is the one modality that answers through opacity.
Future alert: Suspected RD with an unseen fundus = B-scan ultrasound; a visible fundus shows a billowing gray retina with a horseshoe tear.
Correct: A) A horseshoe-shaped retinal tear
Concept: Horseshoe tear = rhegmatogenous mechanism Recall
Why A: A horseshoe tear (a U-shaped full-thickness retinal break with an operculated flap) is the structural abnormality that lets liquefied vitreous track under the retina - the rhegmatogenous mechanism. The billowing elevated gray retina plus a tear confirms detachment and explains it.
Discriminator: The tear IS the mechanism - rhegmatogenous means 'from a break'; without a tear, look for tractional or exudative causes.
| B) Diffuse dot-blot hemorrhages in all quadrants | Dot-blot hemorrhages in all quadrants are CRVO findings, not detachment |
| C) A cherry-red spot at the fovea | Cherry-red spot belongs to CRAO |
| D) Cup-to-disc ratio of 0.8 bilaterally | A high cup-to-disc ratio is glaucoma's signature, unrelated to the detachment |
| E) Keratic precipitates on the corneal endothelium | Keratic precipitates are uveitis debris, not a detachment sign |
Trap: Mechanism trap - matching the tear to the mechanism is the tested step; examine for the horseshoe on the elevated retina.
Future alert: Elevated billowing retina + horseshoe tear = rhegmatogenous RD; quadrant, macula status, and extent determine surgery.
Correct: B) Surgery within 24 hours (scleral buckle or vitrectomy) to preserve foveal function
Concept: Macula-on detachment - urgent surgery within 24 hours Analysis
Why B: A macula-on retinal detachment is a surgical emergency: once the macula detaches, central vision may never fully recover, even after anatomical reattachment. Surgery (scleral buckle or pars plana vitrectomy) within 24 hours maximizes the chance of preserving 20/20 vision.
Discriminator: Macula-on = 24-hour surgery; macula-off = still urgent but vision is already at stake - the macula status is everything.
| A) Observation with monthly follow-up while the macula is attached | Observation allows the detachment to extend to the macula and permanently cost central vision |
| C) Laser photocoagulation of the macula | Laser photocoagulation cannot reattach an already detached retina - it only seals tears |
| D) Anti-VEGF injection | Anti-VEGF treats edema and neovascularization, not a rhegmatogenous detachment |
| E) Topical steroids and cycloplegics | Steroids and cycloplegics are uveitis therapy, not detachment surgery |
Trap: Urgency trap - the temptation is to 'wait and watch'; macula-on detachments are fixed within 24 hours.
Future alert: Rhegmatogenous RD: macula attached = surgery within 24 h; macula off = same-day but vision prognosis limited.
Correct: B) Bilateral vitreous hemorrhage from proliferative diabetic retinopathy
Concept: Vitreous hemorrhage - PDR in a longstanding diabetic Interpretation
Why B: Sudden painless visual loss with cobweb-like floaters and a red haze in a longstanding diabetic signals vitreous hemorrhage from proliferative diabetic retinopathy - the most common cause of vitreous hemorrhage overall. Neovessels rupture during vitreous contraction and bleed into the vitreous cavity.
Discriminator: Cobwebs + red haze + longstanding diabetes = vitreous hemorrhage; PDR is the number one cause.
| A) Bilateral central retinal artery occlusion | CRAO is unilateral severe loss with a cherry-red spot, not bilateral cobwebs |
| C) Bilateral acute angle-closure glaucoma | Angle-closure is a painful red eye with a rock-hard globe - no cobwebs |
| D) Bilateral optic neuritis | Optic neuritis is unilateral pain on eye movement with a central scotoma |
| E) Bilateral retinal detachment from trauma | Traumatic detachments need trauma; the diabetes here is the engine |
Trap: Cause trap - the diabetes history is the lock; PDR is the single most common cause of vitreous hemorrhage.
Future alert: Cobweb floaters + red haze in a diabetic = vitreous hemorrhage from PDR; diabetic control and PRP history decide management.
Correct: B) B-scan ultrasound
Concept: B-scan in vitreous hemorrhage - rule out detachment behind the blood Interpretation
Why B: When the vitreous is filled with blood and the fundus is invisible, B-scan ultrasound is mandatory: it detects an unsuspected retinal detachment behind the hemorrhage and determines whether vitrectomy must be expedited.
Discriminator: Dense vitreous hemorrhage + unseen fundus = B-scan; the detachment you cannot see is the one that blinds.
| A) Fluorescein angiography | Angiography needs a visible fundus and images vessels, not anatomy through hemorrhage |
| C) Optical coherence tomography | OCT cannot penetrate dense vitreous hemorrhage to image the retina |
| D) Computed tomography of the orbit | Orbital CT does not resolve an intraocular detachment |
| E) Color Doppler imaging of the carotid | Carotid Doppler is a stroke workup, irrelevant here |
Trap: Repeat tool trap - B-scan is the answer whenever media opacity hides the retina, exactly as in suspected RD.
Future alert: Any case where blood hides the retina: B-scan first - it decides urgent vitrectomy for RD vs observation for simple hemorrhage.
Correct: B) Observation with head elevation at 30-45 degrees, avoid Valsalva, and strict diabetic control; panretinal photocoagulation later
Concept: Vitreous hemorrhage - conservative first when the retina is attached Analysis
Why B: A vitreous hemorrhage with an attached retina is managed conservatively initially: head elevation at 30-45 degrees lets blood settle below the visual axis, avoid straining/Valsalva to limit rebleeding, and treat the underlying cause (diabetic control; PRP for PDR after the view clears). Vitrectomy is reserved for non-clearing hemorrhage (~3 months) or detachment.
Discriminator: Attached retina = conservative: elevate, avoid Valsalva, control sugar; vitrectomy only if it fails to clear or the retina detaches.
| A) Immediate vitrectomy | Vitrectomy is not first-line with an attached retina - observation is standard and many clear on their own |
| C) Intravitreal anti-VEGF injection | Anti-VEGF treats macular edema/neovascular disease, not a settled clot; it is not the initial step |
| D) Laser peripheral iridotomy | LPI is angle-closure therapy, unrelated |
| E) Systemic anticoagulation | Anticoagulation risks rebleeding and worsens the hemorrhage |
Trap: Over-intervention trap - the urge is surgery; observation with positioning is the textbook first move when attached.
Future alert: Vitreous hemorrhage + attached retina: elevate head 30-45, no Valsalva, treat the cause; vitrectomy if not clearing in about 3 months.
Correct: B) Pars plana vitrectomy to clear the media
Concept: Vitrectomy for chronic non-clearing vitreous hemorrhage Analysis
Why B: When a vitreous hemorrhage fails to clear after roughly 3 months (and diabetic vitrectomy is also indicated for tractional detachment), pars plana vitrectomy is the definitive step - it restores vision and clears the way for PRP if proliferative disease persists.
Discriminator: 12 weeks of non-clearing hemorrhage = the vitrectomy threshold; the attached retina no longer argues for waiting.
| A) Continue observation for another 6 months | Waiting past the 3-month mark forfeits vision without benefit - the surgical threshold has been reached |
| C) Systemic corticosteroids | Steroids do not clear a settled vitreous clot |
| D) Topical antibiotics | Antibiotics treat infection, not hemorrhage |
| E) Bilateral laser iridotomy | LPI is angle-closure therapy - unrelated to vitreous blood |
Trap: Threshold trap - the tested number is the 3-month non-clearing window; after it, vitrectomy, not more patience.
Future alert: Non-clearing vitreous hemorrhage beyond 3 months = pars plana vitrectomy; also urgent vitrectomy if detachment or a break appears.
Correct: B) Optic neuritis (retrobulbar)
Concept: Optic neuritis - the classic presentation in a young woman Interpretation
Why B: Subacute unilateral vision loss, pain on eye movement (present in 90%), dyschromatopsia, RAPD, and a central scotoma in a young woman is optic neuritis until proven otherwise. A normal fundus means retrobulbar neuritis (two-thirds of cases); a swollen disc is papillitis.
Discriminator: Young woman + pain on eye movement + washed-out colors + RAPD = optic neuritis, even with a normal disc.
| A) Open-angle glaucoma | Glaucoma is bilateral, painless, and slowly progressive - no acute scotoma or eye-movement pain |
| C) Central retinal artery occlusion | CRAO is acute, severe, painless with a cherry-red spot - not subacute in a 28-year-old |
| D) Papilledema from raised intracranial pressure | Papilledema is bilateral disc swelling from raised ICP, usually without early vision loss |
| E) Retinal detachment | Detachment gives flashes, floaters, and a curtain - not eye-movement pain and a scotoma |
Trap: Normal-disc trap - retrobulbar neuritis has a normal fundus; the RAPD is the objective sign that carries the diagnosis.
Future alert: Optic neuritis: subacute loss + pain on movement + RAPD + central scotoma; two-thirds are retrobulbar with a normal disc.
Correct: A) MRI of the brain and orbits with gadolinium
Concept: Optic neuritis - MRI defines future MS risk Interpretation
Why A: Gadolinium-enhanced MRI of the brain and orbits is the key investigation in optic neuritis: brain white-matter lesions predict MS. Prognosis stratifies by lesion load - about 50% progress to clinically definite MS at 15 years in patients with two or more lesions versus about 25% with a normal scan.
Discriminator: MRI is prognostic, not just diagnostic - lesion count converts an eye event into an MS-risk statement.
| B) Chest X-ray | CXR screens sarcoidosis or TB - appropriate only in atypical/granulomatous uveitis contexts |
| C) Serum ACE level | ACE screens sarcoidosis, not MS risk |
| D) Fluorescein angiography | Angiography images the retinal vessels - not the optic nerve or brain |
| E) Optical coherence tomography of the macula | Macular OCT does not predict MS - the brain scan does |
Trap: Prognosis trap - the question asks risk of MS, so the answer must stratify brain lesions, not confirm the eye diagnosis.
Future alert: Optic neuritis: MRI with gadolinium; 2+ brain lesions = ~50% MS at 15 years; normal brain MRI = ~25%.
Correct: B) Intravenous methylprednisolone 1 g daily for 3 days followed by an oral taper
Concept: ONTT - IV steroids are the evidence-based regimen Recall
Why B: The ONTT established that IV methylprednisolone 1 g daily for 3 days then a short oral taper hastens recovery and reduces the risk of a second attack at 2 years; oral prednisone alone was associated with a HIGHER rate of new episodes and is avoided.
Discriminator: IV methylprednisolone, not oral prednisone alone - the ONTT is the evidence anchor and the oral-only option is the trap.
| A) Oral prednisone 60 mg daily for 14 days | Oral prednisone alone was linked to an increased rate of recurrence in the ONTT - explicitly avoided |
| C) Topical steroids around the eye | Topical steroids cannot reach the retrobulbar nerve |
| D) No treatment - watchful waiting only | Active optic neuritis is treated to hasten recovery - watchful waiting is not the studied approach |
| E) Oral doxycycline for 7 days | Doxycycline treats infection, not demyelination |
Trap: Evidence trap - the ONTT's counterintuitive finding (oral steroids worse) is a favored exam question.
Future alert: ONTT: IV methylprednisolone 1 g x 3 days then oral taper; oral prednisone alone raises recurrence and is contraindicated.
Correct: B) Recovery of vision to 20/40 or better in about 90% within one year
Concept: Optic neuritis prognosis - good recovery in most Recall
Why B: Most patients do well: roughly 90% recover to 20/40 or better within one year, although subtle deficits (mild color desaturation or contrast loss) often persist. The recovery expectation is central to counseling and a common question.
Discriminator: 90% reach 20/40 or better within a year - the prognosis is good even though residual subtle deficits are common.
| A) Permanent loss of light perception in the affected eye | Severe permanent loss is the minority course - most recover well |
| C) Progressive decline requiring surgery in most cases | No surgery restores optic neuritis; surgery is not part of the treatment pathway |
| D) Recovery only with intravitreal steroids | Intravitreal steroids are not the studied treatment - IV steroids are systemic |
| E) Guaranteed bilateral blindness within 5 years | Bilateral blindness is not the natural history of typical optic neuritis |
Trap: Counseling trap - knowing the good prognosis stops both despair and over-treatment.
Future alert: Optic neuritis prognosis: ~90% recover to 20/40 or better in 1 year; counsel for residual subtle color or contrast deficits.
Correct: B) Primary open-angle glaucoma
Concept: POAG - silent disease, cup-to-disc asymmetry is the clue Interpretation
Why B: POAG is asymptomatic until advanced: elevated IOP, open angles, optic nerve cupping (C:D asymmetry >0.2 between eyes is a classic red flag), and early nasal-step visual field loss define it. The patient is symptom-free - unlike every other entity on this list.
Discriminator: Asymptomatic + open angle + cupping asymmetry + nasal step = POAG; the symptom-free presentation is the essence of the disease.
| A) Acute angle-closure glaucoma | Angle-closure is a painful red eye with halos - not a silent finding |
| C) Optic neuritis | Optic neuritis is acute with pain on eye movement and vision loss |
| D) Papilledema | Papilledema is bilateral disc swelling from raised intracranial pressure |
| E) Anterior uveitis | Uveitis is a painful red eye with photophobia |
Trap: Silent-trap - POAG gives no symptoms; the cupping asymmetry (>0.2) is the finding that forces the diagnosis.
Future alert: POAG: IOP + open angle + cupping asymmetry >0.2 + nasal step; asymptomatic - screening is the only way to catch it.
Correct: B) Prostaglandin analogues (latanoprost)
Concept: First-line POAG therapy - prostaglandin analogues Recall
Why B: Prostaglandin analogues (latanoprost 0.005% nightly) are first-line: they lower IOP by increasing uveoscleral outflow, are once-daily at bedtime, and show the best effect with few systemic side effects. Timolol remains a common alternative but has systemic effects (bradycardia, bronchospasm).
Discriminator: Latanoprost is the modern first line - once nightly, uveoscleral outflow, best efficacy-to-side-effect ratio.
| A) Beta-blockers (timolol) | Timolol is effective but second-line now because of systemic effects - and it is the wrong answer for 'usual first-line' |
| C) Carbonic anhydrase inhibitors (dorzolamide) | Dorzolamide is an adjunct, not the initial single agent |
| D) Alpha-agonists (brimonidine) | Brimonidine is an adjunct, not the usual first line |
| E) Hyperosmotics (mannitol IV) | Mannitol is acute angle-closure therapy, not chronic POAG care |
Trap: First-line trap - the old reflex was timolol; the modern first-line answer is the prostaglandin analogue.
Future alert: POAG first-line = prostaglandin analogue nightly; add beta-blocker/CAI/alpha-agonist as monotherapy fails; mannitol is never chronic.
Correct: B) Reactive airway disease (asthma) or COPD with bronchospasm
Concept: Timolol contraindications - respiratory and cardiac Recall
Why B: Topical beta-blockers (timolol) reach the systemic circulation through the nasolacrimal duct and can cause bronchospasm in asthma/COPD and bradycardia/heart block in cardiac disease. Reactive airway disease is the classic contraindication and the most tested one.
Discriminator: Systemic absorption of timolol means the contraindications are systemic: asthma/COPD and bradyarrhythmias.
| A) Mild hypertension | Mild hypertension is not a contraindication - beta-blockers lower BP, which is usually tolerable |
| C) Type 2 diabetes controlled on metformin | Diabetes is not a beta-blocker contraindication (glycemic masking is a warning, not a bar) |
| D) Gastroesophageal reflux disease | GERD is unrelated |
| E) Benign prostatic hyperplasia | BPH is unrelated to beta-blocker use |
Trap: Route trap - eyedrops are not 'local': nasolacrimal absorption makes every systemic contraindication apply.
Future alert: Timolol contraindicated in asthma/COPD, bradycardia, heart block; ask about lung and pulse before prescribing any topical beta-blocker.
Correct: A) It is the leading cause of irreversible blindness worldwide in Black populations, with higher prevalence and earlier onset
Concept: POAG epidemiology - leading irreversible blindness, Black populations hardest hit Recall
Why A: POAG is a leading cause of irreversible blindness worldwide; people of African descent have a 3-4 times higher prevalence, earlier onset, and more severe disease. The optic nerve damage is irreversible - which is why screening and early treatment matter.
Discriminator: Irreversible + 3-4x in Black populations + earlier and more severe = the epidemiological signature of POAG.
| B) It always presents with painful red eyes and halos | Painful red eye with halos is acute angle-closure, not POAG - POAG is silent |
| C) It affects men exclusively over age 80 | Both sexes are affected; risk rises with age but not exclusively in men over 80 |
| D) It is reversible with laser peripheral iridotomy | LPI treats angle-closure, not open-angle disease |
| E) It causes no visual field loss until total blindness | Visual field loss is early and progressive (nasal step first), not deferred until blindness |
Trap: Epidemiology trap - the exam pairs POAG facts against angle-closure facts; the irreversible-Black-prevalence pairing is the lock.
Future alert: POAG: leading cause of irreversible blindness; 3-4x prevalence and earlier in Black populations - screen early, treat early.
Correct: A) Mild nonproliferative diabetic retinopathy - annual dilated eye examination plus glycemic control
Concept: Mild NPDR - microaneurysms only, annual review Interpretation
Why A: Microaneurysms as the sole finding define mild NPDR: annual, dilated fundoscopy plus aggressive control of glucose, blood pressure, and lipids. This earliest stage does not need laser or injection - the plan is surveillance and systemic control.
Discriminator: Only microaneurysms = mild NPDR; the treatment is annual review and control, not intervention.
| B) Proliferative diabetic retinopathy - urgent panretinal photocoagulation | PDR requires neovascularization - absent here; PRP would be over-treatment |
| C) Severe NPDR - immediate PRP | Severe NPDR follows the 4-2-1 rule - absent here |
| D) Vitreous hemorrhage - vitrectomy | Vitreous hemorrhage is a PDR complication with vision loss |
| E) Central retinal vein occlusion - anti-VEGF | CRVO has a blood-and-thunder fundus - not microaneurysms alone |
Trap: Over-treatment trap - the earliest stage invites no laser; annual surveillance is the correct, tested answer.
Future alert: Mild NPDR = microaneurysms only: annual dilated exam + glycemic/BP/lipid control; no laser at this stage.
Correct: A) Four quadrants of venous beading (or two quadrants of IRMA, or any quadrant with venous beading) in a single eye - follow-up every 2-4 months, consider PRP
Concept: Severe NPDR - the 4-2-1 rule and tight follow-up Recall
Why A: The 4-2-1 rule defines severe NPDR: hemorrhages/microaneurysms in all four quadrants, OR venous beading in two or more quadrants, OR IRMA in one quadrant. These eyes are at high risk of progression to PDR, so follow-up every 2-4 months is required and PRP may be considered (the ETDRS recommends considering scatter photocoagulation).
Discriminator: 4-2-1 = spread and severity of ischemia markers; the answer is tight follow-up, not waiting a year.
| B) Four disc areas of neovascularization - immediate vitrectomy | Neovascularization defines PDR, not NPDR - and vitrectomy is not the immediate step |
| C) Two new-onset floaters - B-scan ultrasound | Floaters are unrelated to the 4-2-1 definition |
| D) One quadrant of hemorrhage - annual review | One quadrant of hemorrhage fails the 4-2-1 threshold (needs all four) |
| E) Four-line drop in acuity - urgent cataract surgery | Acuity drops are not part of this staging rule |
Trap: Rule trap - the 4-2-1 components must be stated exactly; memorizing the rule IS the question.
Future alert: 4-2-1 = severe NPDR: 4-quadrant hemorrhages, 2-quadrant venous beading, or 1-quadrant IRMA -> close follow-up 2-4 months, consider PRP.
Correct: B) Panretinal photocoagulation (PRP) - indicated for high-risk proliferative diabetic retinopathy
Concept: PDR with NVD = high-risk features -> PRP Interpretation
Why B: NVD at the disc is a high-risk characteristic of proliferative diabetic retinopathy. PRP is indicated to induce regression of neovascularization and prevent vitreous hemorrhage and tractional detachment; it is the definitive treatment for high-risk PDR.
Discriminator: New vessels on the disc = high-risk PDR; PRP is the answer, not surveillance.
| A) Annual review as before | Annual review suits mild NPDR - NVD escalates the eye into the laser lane |
| C) Observation until symptoms develop | Waiting for symptoms (hemorrhage) forfeits the preventive window of PRP |
| D) Intravitreal antibiotics | Antibiotics treat infection, not neovascularization |
| E) Cataract surgery immediately | Cataract surgery is unrelated to this finding |
Trap: Escalation trap - mild NPDR annual review is the right answer only until the stage changes; NVD changes everything.
Future alert: NVD/NVE = PDR: PRP to regress new vessels; prevention of vitreous hemorrhage is the goal.
Correct: B) Diabetic macular edema - anti-VEGF injections (ranibizumab, bevacizumab, aflibercept)
Concept: Diabetic macular edema - anti-VEGF first-line Interpretation
Why B: Hard exudates at the macula in a diabetic = diabetic macular edema - the leading cause of visual loss in NPDR. Anti-VEGF injections are first-line (ranibizumab, bevacizumab, aflibercept); focal/grid laser is no longer the primary therapy for center-involving edema.
Discriminator: Macular hard exudates in a diabetic = DME; the treatment lane moved from laser to anti-VEGF.
| A) Cystoid macular edema from cataract - vitrectomy | This is not cystoid edema from cataract; the diabetic history and exudates are the lock |
| C) Macular hole - gas tamponade | Macular hole gives a round central defect on OCT - not hard exudates |
| D) Central serous retinopathy - oral acetazolamide | Central serous retinopathy is a bullous serous detachment, unrelated to diabetes |
| E) Epiretinal membrane - membrane peel | Epiretinal membrane causes metamorphopsia, not hard exudates at the macula |
Trap: Old-guideline trap - focal laser was once first-line for DME; anti-VEGF is the modern answer.
Future alert: DME: hard exudates at the macula -> anti-VEGF first-line; laser is an adjunct, no longer primary for center-involving edema.
Correct: A) At diagnosis, because up to 20% already have retinopathy, then at least annually
Concept: Screening timing - T2DM screens at diagnosis Interpretation
Why A: Up to 20% of patients with type 2 diabetes already have retinopathy AT diagnosis (because the disease is often present years before detection), so the first dilated retinal examination happens immediately at diagnosis, then annually. Type 1 diabetics are screened 5 years after diagnosis; pregnancy adds a first-trimester examination.
Discriminator: T2DM = screen at diagnosis (20% already affected); T1DM = 5 years after onset; pregnancy = first trimester.
| B) In five years, since retinopathy takes years to develop | Five years is the TYPE 1 rule; type 2 has had occult disease for years by diagnosis |
| C) Only if she develops visual symptoms | Waiting for symptoms misses the preventable window - retinopathy is initially silent |
| D) At age 50, regardless of diabetes duration | Age alone is irrelevant; duration of diabetes drives the risk |
| E) Never - type 2 diabetes does not cause retinopathy | Type 2 diabetes is a leading cause of blindness - it absolutely causes retinopathy |
Trap: Timing trap - the exam swaps the T1DM and T2DM rules; the diagnosis-point screen for type 2 is the tested fact.
Future alert: Diabetic screening: T2DM at diagnosis then annual; T1DM 5 years after onset; pregnancy - first trimester and follow the pregnancy.
Correct: B) Posterior communicating artery aneurysm compressing the third nerve - urgent CTA/MRA and neurosurgical evaluation
Concept: Pupil-involved CN III palsy = posterior communicating aneurysm emergency Interpretation
Why B: A third nerve palsy with a dilated, non-reactive pupil (pupil-involved) localizes to the superficial surface of the nerve where the pupillomotor fibers travel - the classic site of posterior communicating artery aneurysm compression. This is a rupturing-aneurysm emergency: urgent CTA/MRA and neurosurgery, not observation.
Discriminator: Pupil involvement = aneurysm until proven otherwise; microvascular (diabetic) palsies spare the pupil.
| A) Diabetic microvascular third nerve palsy - observe and control glucose | Microvascular diabetic palsy classically SPARES the pupil and is not an emergency |
| C) Myasthenia gravis - edrophonium test | Myasthenia gives fatigable, variable weakness without a fixed mydriatic pupil |
| D) Multiple sclerosis - MRI brain | MS causes internuclear ophthalmoplegia, not this pupil-involved third palsy |
| E) Orbital cellulitis - intravenous antibiotics | Cellulitis would show proptosis, erythema, fever, and pain - not isolated ptosis and diplopia |
Trap: Pupil trap - the pupil is the whole question: involved = surgical aneurysm, spared = microvascular medical disease.
Future alert: CN III palsy with dilated fixed pupil = posterior communicating aneurysm until excluded - CTA/MRA same day, neurosurgery.
Correct: B) Microvascular (ischemic) third nerve palsy - pupil-sparing, resolves over about 3 months
Concept: Pupil-sparing CN III palsy in a diabetic = microvascular Interpretation
Why B: A pupil-sparing third nerve palsy in an older patient with microvascular risk factors (hypertension, diabetes) is ischemic microvascular disease: the vasa nervorum infarcts, and because the pupillomotor fibers sit peripherally (most protected from central ischemia), the pupil is spared. It resolves spontaneously over about 3 months; the workup targets the risk factors.
Discriminator: Pupil-sparing + diabetic/ hypertensive = microvascular; the pupil-sparing pattern is what keeps the aneurysm off the table.
| A) Posterior communicating artery aneurysm - urgent coiling | Aneurysm disease is pupil-INVOLVED - this palsy puts the pupil outside the danger zone |
| C) Raised intracranial pressure - urgent lumbar puncture | Raised ICP causes bilateral VI palsies or papilledema - not an isolated pupil-sparing third nerve palsy |
| D) Thyroid eye disease - orbital decompression | Thyroid eye disease limits elevation and retracts the lid - no fixed down-and-out pattern |
| E) Cavernous sinus thrombosis - anticoagulation | Cavernous sinus thrombosis is painful with proptosis, chemosis, and fever - not this picture |
Trap: Pattern trap - the course (months, self-limited) and the spared pupil are inseparable; treating a pupil-sparing palsy as an aneurysm is the wrong emergency.
Future alert: Pupil-sparing CN III palsy in a diabetic/hypertensive = microvascular: check BP, HbA1c, lipids; observe; resolves ~3 months.
Correct: C) Left abducens nerve (VI)
Concept: Inability to abduct = sixth nerve palsy Recall
Why C: The sixth (abducens) nerve innervates the lateral rectus; failure to abduct with an esotropia (crossed eye, worse at distance) is a sixth nerve palsy. Absent ptosis and a normal pupil rule out third nerve disease, and the abducting deficit is not trochlear (which tilts and fails depression in adduction).
Discriminator: Esotropia + failure to abduct = VI palsy; the abducting muscle is the lateral rectus and VI is its nerve.
| A) Left oculomotor nerve (III) | III nerve disease gives ptosis plus a down-and-out eye with possible pupil involvement - neither is present |
| B) Left trochlear nerve (IV) | IV palsy causes hypertropia worse on down-gaze and head tilt - not an esotropia on abduction |
| D) Right oculomotor nerve (III) | The deficit is in the LEFT eye abducting - the left VI is the culprit, not the right III |
| E) Right trochlear nerve (IV) | Trochlear disease does not produce failure of abduction |
Trap: Direction trap - map the action to the muscle to the nerve: abduction failure = lateral rectus = VI.
Future alert: Esotropia, worse at distance, no ptosis, failure to abduct = sixth nerve palsy; causes span microvascular, raised ICP, and cavernous sinus disease.
Correct: B) Myasthenia gravis
Concept: Fatigable ptosis and variable diplopia = myasthenia Interpretation
Why B: Fatigability (worse at day's end), variability during the examination, and ptosis that worsens on sustained upgaze are the myasthenia signature - it fluctuates, unlike fixed cranial nerve palsies. The normal pupil is also characteristic: myasthenia never affects the pupil.
Discriminator: Variable + fatigable + pupil-normal = myasthenia; fixed deficits with a dilated pupil are the opposite category.
| A) Third nerve palsy from an aneurysm | Aneurysmal third palsy is fixed, sudden, and pupil-dilated - none of that is here |
| C) Sixth nerve palsy from raised ICP | Raised ICP gives a fixed abducens deficit, not fatigable variability |
| D) Thyroid eye disease | Thyroid eye disease is non-fatigable with lid retraction and proptosis |
| E) Internuclear ophthalmoplegia from MS | INO gives a specific adduction failure on conjugate gaze testing - not fatigable fluctuating ptosis |
Trap: Fluctuation trap - the exam plants temporal variation and fatigue; those belong to myasthenia alone among the diplopia causes.
Future alert: Fatigable ptosis + variable diplopia + normal pupils = myasthenia; edrophonium test and anti-AChR antibodies confirm.
Correct: B) Papilledema from idiopathic intracranial hypertension (IIH)
Concept: IIH - classic demographic plus transient visual obscurations Interpretation
Why B: A young obese woman with morning headaches, pulsatile tinnitus, transient visual obscurations (seconds-long darkening, posture-related), and BILATERAL disc swelling with intact acuity = idiopathic intracranial hypertension. The bilateral swelling with preserved vision and no RAPD separates it from optic neuritis.
Discriminator: Bilateral disc swelling + young obese woman + TVOs + preserved acuity = IIH; the unilateral pain pattern would point to neuritis.
| A) Bilateral optic neuritis | Optic neuritis is typically unilateral with pain on eye movement, RAPD, and central scotoma - not this symmetric picture |
| C) Bilateral central retinal vein occlusion | Bilateral CRVO in a 28-year-old is vanishingly rare and would drop vision markedly |
| D) Malignant hypertension | Malignant hypertension gives hypertensive retinopathy with very high BP, not this indolent headache pattern |
| E) Optic nerve drusen | Drusen are usually asymptomatic, discovered incidentally, without headaches and TVOs |
Trap: Demographic trap - young obese woman + TVOs + bilateral swelling is the IIH lock; do not be pulled to optic neuritis by 'disc swelling' alone.
Future alert: Young obese woman + morning headache + TVOs + bilateral disc swelling = IIH; next step is imaging to exclude mass BEFORE lumbar puncture.
Correct: B) MRI and MR venography FIRST to exclude a mass or venous sinus thrombosis, then lumbar puncture; opening pressure above 25 cm H2O (with normal CSF) confirms IIH
Concept: Papilledema workup - imaging before LP; opening pressure threshold Analysis
Why B: Papilledema means raised intracranial pressure, so imaging (MRI + MRV) must come BEFORE lumbar puncture to exclude a mass or venous sinus thrombosis - doing an LP first in a patient with a mass risks herniation. IIH is confirmed by an opening pressure above 25 cm H2O with normal CSF content.
Discriminator: Imaging before LP is a safety mandate; the opening-pressure number (25 cm H2O) with normal CSF is the diagnostic lock.
| A) Lumbar puncture first, then MRI if cerebrospinal fluid pressure is elevated | LP first is dangerous - herniation risk if a mass is present |
| C) CT angiography of the brain only | CT angiography is for vascular lesions and does not rule out the mass/venous thrombosis spectrum or measure pressure |
| D) Visual fields first, and treatment only if fields are abnormal | Fields tell severity, not the diagnosis; they come after imaging and LP |
| E) No imaging needed - fundoscopy alone confirms papilledema | Fundoscopy shows swelling but cannot prove ICP is raised - measured pressure is the diagnosis |
Trap: Sequence trap - the exam tests whether you know LP comes AFTER imaging in any papilledema workup.
Future alert: Papilledema: MRI + MRV first (exclude mass/venous sinus thrombosis), then LP; opening pressure >25 cm H2O with normal CSF = IIH.
Correct: B) Weight loss of 5-10% plus acetazolamide, escalating to surgery if vision deteriorates
Concept: IIH treatment pyramid - weight loss and acetazolamide first Recall
Why B: Treatment is graduated: weight loss of 5-10% is the most effective disease-modifying step, plus acetazolamide (500 mg to 1 g twice daily) which reduces CSF production. Serial LP, optic nerve sheath fenestration, or shunting are reserved for vision-threatening or refractory disease.
Discriminator: Start with weight loss + acetazolamide; surgery is for vision loss, not first-line.
| A) Immediate optic nerve sheath fenestration | Surgery (fenestration) is a vision-salvage escalation, not the opening move |
| C) Chronic oral steroids | Steroids are not IIH therapy - they do not lower CSF pressure and have their own risks |
| D) Lumbar drain for one week | A lumbar drain is temporary and invasive, not a treatment plan |
| E) Neurosurgical shunt on diagnosis | Shunting at diagnosis over-treats; most IIH responds to weight loss and acetazolamide |
Trap: Staging trap - the exam escalates treatment too fast; the pyramid (lifestyle and drug first) is the graded answer.
Future alert: IIH: weight loss 5-10% + acetazolamide first-line; add serial LP; fenestration or shunt only if vision deteriorates.
Correct: B) Pseudopapilledema from optic disc drusen - no true swelling, autofluorescence or B-scan can confirm buried drusen
Concept: Pseudopapilledema - disc drusen mimic swelling Analysis
Why B: Bilateral disc elevation in an asymptomatic patient is the classic pseudopapilledema scenario: buried optic disc drusen create a lumpy, elevated disc that mimics swelling without raised ICP. Autofluorescence (drusen fluoresce) or B-scan ultrasound can confirm buried drusen - the key is not to treat a normal-pressure disc as papilledema.
Discriminator: No symptoms + bilateral elevated discs = suspect drusen; the disc does not truly swell and the pressure is normal.
| A) Optic neuritis - the presence of pain on eye movement and a unilateral RAPD | Neuritis is symptomatic with pain and RAPD - the stem explicitly lacks all of it |
| C) Glaucomatous cupping - increased cup-to-disc ratio | Glaucoma cups the disc; it does not elevate it - and the IOP history is absent |
| D) Retinitis pigmentosa - bone spicule pigmentation | Retinitis pigmentosa shows bone spicules and night blindness, not isolated disc elevation |
| E) Choroidal melanoma - pigmented mass | Melanoma is a pigmented mass lesion, not bilateral disc elevation |
Trap: Mimic trap - the asymptomatic bilateral elevated disc is the drusen trap; imaging (autofluorescence/B-scan) prevents a needless LP.
Future alert: Asymptomatic bilateral disc elevation = suspect buried drusen; confirm with autofluorescence/B-scan before any ICP workup.
This MedCORE is not a medical textbook. It is only designed for rapid, last-minute recall and should be treated like a high-yield cheat sheet, not a complete learning resource. Use it to memorize critical algorithms and recognition patterns.